GRIN Therapeutics, Inc.

Advancing a targeted approach to the treatment of GRIN-related disorders and other types of pediatric neurodevelopmental disorders.

[GRIN Therapeutics, Inc. @GRIN_tx]

We’re looking forward to #ESHG2026 in Gothenburg, Sweden. We’ll share insights from our ongoing clinical development of investigational radiprodil as a targeted approach for GRIN-related neurodevelopmental disorder. #RareDisease

[GRIN Therapeutics, Inc. @GRIN_tx]

We’re looking forward to joining the epilepsy community in Japan for #JSCN2026. Concurrently, we’ll attend the ISS Annual Meeting and share updates from our global Phase 3 Beeline study of investigational radiprodil for GRIN-related neurodevelopmental disorder. #RareDisease

[GRIN Therapeutics, Inc. @GRIN_tx]

At the @GlobalGenes and @RareEpilepsy RAD Brain Workshop, GRIN Therapeutics discussed our work in GRIN-NDD, including the science behind investigational radiprodil, updates on the global Phase 3 Beeline trial, and patient advocacy across the drug development process.

[GRIN Therapeutics, Inc. @GRIN_tx]

This #TSCGlobalDay, we stand with the international TSC community. We also want to thank TSCi, E-TSC, TSC Alliance, and other patient organizations for their tireless support, advocacy, and guidance. Learn about resources for those living with TSC here: https://t.co/mkC2EwnPx6

[GRIN Therapeutics, Inc. @GRIN_tx]

We are proud to participate in the first-ever GRI UK Family Conference, where our team will present updates on the global Phase 3 Beeline trial for GRIN-NDD. Learn more about GRI UK and their mission here: https://t.co/erwgAqU3aH

[GRIN Therapeutics, Inc. @GRIN_tx]

Our team was pleased to be at #DICE2026, where we explored the latest research, clinical insights, and therapeutic strategies related to epilepsy, highlighting encouraging progress for both DEEs and GRIN-related neurodevelopmental disorder.

[GRIN Therapeutics, Inc. @GRIN_tx]

Tuberous sclerosis complex (TSC) is a multi-system genetic condition caused by mutations in the TSC1 or TSC2 genes. For #TSCAwarenessMonth, we proudly join the patient and advocacy community in raising awareness and supporting individuals worldwide affected by this condition.

[GRIN Therapeutics, Inc. @GRIN_tx]

Our pivotal Phase 3 Beeline trial has expanded to sites in Europe, bringing new levels of momentum in our global program evaluating investigational radiprodil for GRIN-NDD with gain-of-function variants. Learn more: https://t.co/HAVnbZ4L7l

[GRIN Therapeutics, Inc. @GRIN_tx]

We look forward to presenting at EILAT XVIII to share updates on investigational radiprodil and its potential to offer a tailored therapeutic option for patients with GRIN-related neurodevelopmental disorder. Learn more: https://t.co/UZ1ngX02FV

[GRIN Therapeutics, Inc. @GRIN_tx]

During #PatientExperienceWeek, we celebrate the voices, insights, and experiences of patients and families - because they are at the center of everything we do. This week, we honor the patients and caregivers whose perspectives guide every step of our work.

[GRIN Therapeutics, Inc. @GRIN_tx]

Did you know that the average rare disease diagnosis takes 5 years? This #UndiagnosedChildrenAwarenessDay, visit @genedx’s website to learn how they are diagnosing rare diseases and delivering hope to families seeking answers: https://t.co/r7FCdQFPij

[GRIN Therapeutics, Inc. @GRIN_tx]

We look forward to participating in @CureGRIN’s #GRICON26 and providing an update on our global Phase 3 Beeline trial for GRIN-related neurodevelopmental disorder (GRIN-NDD). Learn more: https://t.co/ZcsJnljAtp

[GRIN Therapeutics, Inc. @GRIN_tx]

This #PatientAccessWeek, we recognize the importance of access. In neurodevelopmental disorders, clinical trial processes can be complex. We remain committed to providing access to advocacy resources and clinical trial information: https://t.co/EGc6cJjIKc

[GRIN Therapeutics, Inc. @GRIN_tx]

Autism can be a feature of several rare neurodevelopmental conditions, and recognizing these conditions helps drive support, awareness, and inclusion. Learn more at @autismspeaks: https://t.co/WOGlsnElyv #WorldAutismDay

[GRIN Therapeutics, Inc. @GRIN_tx]

This #PurpleDay, we recognize the resilience of those affected by epilepsy and renew our commitment to research that looks beyond seizures, helping to bring hope and better solutions to the broader community.

[GRIN Therapeutics, Inc. @GRIN_tx]

From March 12–18, we join the GRIN community in recognizing GRIN2B Awareness Week. Visit @GRIN2Bsyndrome's to explore resources and learn more about this growing community: https://t.co/9gvPrZCIuz

[GRIN Therapeutics, Inc. @GRIN_tx]

Recently, the @AmerAcadPeds updated its guidelines for evaluating children with intellectual disability (ID) or global developmental delay (GDD), Learn more from AAP: https://t.co/S6OqTtr3Lz

[GRIN Therapeutics, Inc. @GRIN_tx]

During Medical Genetics Awareness Week, we recognize the critical role of genetic testing in diagnosing rare neurodevelopmental disorders.

[GRIN Therapeutics, Inc. @GRIN_tx]

Patient safety is at the heart of everything we do at GRIN Therapeutics. This #PatientSafetyAwarenessWeek, we are proud to honor the trust families place in us and remain focused on advancing research while keeping safety at the forefront of every study.

[GRIN Therapeutics, Inc. @GRIN_tx]

This month is GRI Disorders Awareness Month —a time to honor the patients, families, clinicians, and researchers who make up the GRIN community.